Integral BioSystems to Exhibit in Booth 4139 at 2019 BIO International Convention in Philadelphia June 3-6, 2019
Boston area drug developer Integral BioSystems to display in Booth 4139 at BIO 2019 in the Philadelphia Convention Center June 3-6,2019
We approach projects with practical, yet out-of-the-box thinking.”
BEDFORD, MA, US, May 13, 2019 /EINPresswire.com/ -- Boston area CRO specializing in innovative pharmaceutical formulation development will be in the spotlight as a participating exhibitor during the 2019 BIO International Convention in the Philadelphia Convention Center on June 3-6, 2019.— Dr. Shikha P. Barman
With over 25 years of experience in all phases of cell and tissue targeted, sustained release pharmaceutical formulation development, the firm’s CEO and President, Dr. Shikha P. Barman, will be on hand to discuss the specific requirements of interested attendees. For those seeking to develop a formulation for a new drug substance, a 505b2 product or a generic drug product, Dr. Barman will be available to answer questions about the suitability of Integral’s recently patented drug delivery platform technologies, NanoM™ and OcuSurf™ for your particular application.
About the Symposium
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations.
The key benefits of attending the BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry thought leaders with over 1,500 education sessions at your fingertips and unparalleled networking opportunities with 16,000+ attendees from 74 countries.
About Integral BioSystems
Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up, and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems.
The Company has developed numerous dosage forms for ophthalmic applications. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes.
Dave Karasic
Integral BioSystems, LLC
617-820-8483
email us here
